Home Metabolism CYP450

CYP450 Inhibitors/Chemicals

CYP450 Products

  • All (3)
  • CYP450 Inhibitors (2)
  • New CYP450 Products
Cat.No. Product Name Information Product Use Citations Product Validations
E5860New 20-HETE 20-HETE-d6 is the deuterated form of 20-hydroxyeicosatetraenoic acid (20-HETE).
E2949New Talarozole (R115866) Talarozole (R115866) is a potent, orally active inhibitor of cytochrome P450 (CYP26)-mediated metabolism of All-trans-retinoic acid (RA). It inhibits the conversion of RA by CYP26, with an IC50 of 0.004 µM, and enhances endogenous RA levels and All-trans-retinoic acid receptor (RAR) activation, showing potential as a targeted agent for dermatological therapy.
E0742 Melengestrol Acetate Melengestrol Acetate, progestational steroid suppress the AT3 tumour.
E2949New Talarozole (R115866) Talarozole (R115866) is a potent, orally active inhibitor of cytochrome P450 (CYP26)-mediated metabolism of All-trans-retinoic acid (RA). It inhibits the conversion of RA by CYP26, with an IC50 of 0.004 µM, and enhances endogenous RA levels and All-trans-retinoic acid receptor (RAR) activation, showing potential as a targeted agent for dermatological therapy.
E0742 Melengestrol Acetate Melengestrol Acetate, progestational steroid suppress the AT3 tumour.
E5860New 20-HETE 20-HETE-d6 is the deuterated form of 20-hydroxyeicosatetraenoic acid (20-HETE).
E2949New Talarozole (R115866) Talarozole (R115866) is a potent, orally active inhibitor of cytochrome P450 (CYP26)-mediated metabolism of All-trans-retinoic acid (RA). It inhibits the conversion of RA by CYP26, with an IC50 of 0.004 µM, and enhances endogenous RA levels and All-trans-retinoic acid receptor (RAR) activation, showing potential as a targeted agent for dermatological therapy.